Multi-die design using 2.5D and 3D technologies has emerged as a necessity to keep the pace of innovation. For all their benefits, these projects present new challenges. This post considers monitoring ...

Shortly after filing for formal FDA approval of its Galleri blood test for cancer screening, Grail has teamed up with telehealth company Hims & Hers to enhance its commercial availability. Galleri is ...

Just weeks after filing for FDA approval of its Galleri blood test for cancer screening, Grail has reported that a flagship trial of the technology in the UK failed to achieve its primary objective.

A blood test which looks for multiple types of cancer has failed to achieve its key objective in a major NHS trial, the company has announced. The Galleri blood test is being trialled on 142,000 NHS ...

Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His ...

VeEX Inc., a global leader in innovative test and measurement solutions for next-generation networks, have introduced the MTX640, a compact, high-performance du ...

The only bit that's missing is is the 'RGB ...

A closely watched clinical trial in Britain that screened blood for early detection of cancer did not show a reduction in diagnoses at later stages of the disease. By Rebecca Robbins and Gina Kolata A ...

A large, three-year clinical trial designed to demonstrate how Grail’s blood test for early cancer detection could work in a broad population has preliminary results showing reduction in late-stage ...

A leading Senate Republican told South Carolina’s top education official Thursday that her decision to welcome home-educated students into the state’s school voucher program had created a “real trust ...

Grail’s shares plummeted more than 45% after-hours Thursday as the medtech revealed a major National Health Service (NHS) trial of its Galleri test missed its primary endpoint. In top-line data ...